Takeda Pharmaceutical Company Ltd
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese Participants
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Takeda
- Target Recruit Count
- 33
- Registration Number
- NCT03085836
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, China
A Study to Evaluate the Bioequivalence of Single Oral Dose of Esomeprazole Capsule and Tablet Formulation in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2017-03-20
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 52
- Registration Number
- NCT03083639
- Locations
- 🇺🇸
Pharmaceutical Research Associates, Inc., Lenexa, Kansas, United States
Cognitive and Mood Assessment Data in Major Depressive Disorder Using Digital Wearable Technology
- Conditions
- Major Depressive Disorder
- Interventions
- Other: No intervention
- First Posted Date
- 2017-03-01
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 30
- Registration Number
- NCT03067506
- Locations
- 🇬🇧
Takeda Investigative Site, London, United Kingdom
Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection
- Conditions
- Gastric Ulcer
- Interventions
- Drug: TAK-438 PlaceboDrug: Bismuth-Containing Quadruple Therapy
- First Posted Date
- 2017-02-10
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 234
- Registration Number
- NCT03050307
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Yijishan hospital of Wan nan Medical college, Wuhu, Anhui, China
🇨🇳Beijing Chao Yang Hospital, Beijing, Beijing, China
Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection
- Conditions
- Duodenal Ulcer
- Interventions
- Drug: TAK-438 PlaceboDrug: Bismuth-Containing Quadruple Therapy
- First Posted Date
- 2017-02-10
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 533
- Registration Number
- NCT03050359
- Locations
- 🇨🇳
Shiyan Taihe Hospital, Shiyan, Hebei, China
🇨🇳Jiangxi Nanchang 3rd Hospital, Nanchang, Jiangxi, China
🇰🇷Korea University Ansan Hospital, Ansan-si, Gyeonggi-do, Korea, Republic of
A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation
- First Posted Date
- 2017-02-03
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 14
- Registration Number
- NCT03042299
- Locations
- 🇯🇵
Nishi Kumamoto Hospital, Kumamoto, Japan
Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2017-02-03
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- Takeda
- Registration Number
- NCT03042325
Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults
- Conditions
- NorovirusHealthy Volunteers
- Interventions
- Biological: NoV Vaccine
- First Posted Date
- 2017-02-01
- Last Posted Date
- 2022-11-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 528
- Registration Number
- NCT03039790
- Locations
- 🇺🇸
Simon-Williamson Clinic/Synexus Clinical Research US, Inc, Birmingham, Alabama, United States
🇺🇸Synexus Clinical Research US, Inc/Southwest Family Medicine, Littleton, Colorado, United States
🇺🇸Miami Research Associates, Miami, Florida, United States
Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease
- Conditions
- Primary Sclerosing CholangitisInflammatory Bowel Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-01-27
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Takeda
- Registration Number
- NCT03035058
Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 278
- Registration Number
- NCT03029143
- Locations
- 🇺🇸
University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
🇺🇸Atlanta Center for Gastroenterology, Decatur, Georgia, United States
🇺🇸Gastroenterology Associates of Northern Virginia, Ltd., Fairfax, Virginia, United States